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Abstract
Background: Cardiac allograft vasculopathy (CAV) is the principal cause of long-term graft failure following heart
transplantation. Early identification of patients at risk of CAV is essential to target invasive follow-up procedures more
effectively and to establish appropriate therapies. We evaluated the prognostic value of the first heart biopsy (median: 9
days post-transplant) versus all biopsies obtained within the first three months for the prediction of CAV and graft failure
due to CAV.
Methods and Findings: In a prospective cohort study, we developed multivariate regression models evaluating markers of
atherothrombosis (fibrin, antithrombin and tissue plasminogen activator [tPA]) and endothelial activation (intercellular
adhesion molecule-1) in serial biopsies obtained during the first three months post-transplantation from 172 patients
(median follow-up=6.3 years; min=0.37 years, max=16.3 years). Presence of fibrin was the dominant predictor in first-
biopsy models (Odds Ratio [OR] for one- and 10-year graft failure due to CAV=38.70, p=0.002, 95% CI=4.00–374.77; and
3.99, p=0.005, 95% CI=1.53–10.40) and loss of tPA was predominant in three-month models (OR for one- and 10-year graft
failure due to CAV=1.81, p=0.025, 95% CI=1.08–3.03; and 1.31, p=0.001, 95% CI=1.12–1.55). First-biopsy and three-
month models had similar predictive and discriminative accuracy and were comparable in their capacities to correctly
classify patient outcomes, with the exception of 10-year graft failure due to CAV in which the three-month model was more
predictive. Both models had particularly high negative predictive values (e.g., First-biopsy vs. three-month models: 99% vs.
100% at 1-year and 96% vs. 95% at 10-years).
Conclusions: Patients with absence of fibrin in the first biopsy and persistence of normal tPA in subsequent biopsies rarely
develop CAV or graft failure during the next 10 years and potentially could be monitored less invasively. Presence of early
risk markers in the transplanted heart may be secondary to ischemia/reperfusion injury, a potentially modifiable factor.
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Introduction
Modern immunosuppressive regimens have reduced the
incidence of acute rejection and extended early survival following
heart transplantation but have done little to reduce the incidence
of cardiac allograft vasculopathy (CAV), the principal long-term
cause of graft failure. CAV, an aggressive form of atherosclerosis
that develops within months to a few years after transplantation,
accounts for 30% of all deaths [1]. Because heart transplant
patients lack premonitory symptoms, CAV first presents clinically
as a silent myocardial infarction, severe arrhythmia, or sudden
death. Thus, research has focused on identifying early predictors
of CAV onset and progression.
The Invasive Monitoring Attenuation through Gene Expression
(IMAGE) trial recently showed that patients at low risk of rejection
can be monitored safely with noninvasive gene-expression
profiling [2]. It might be possible to devise a similar noninvasive
strategy to monitor CAV, provided that low-risk patients could be
reliably identified. We recently showed that absence of athero-
thrombotic risk markers in the first three months post-transplan-
tation identifies patients that rarely develop CAV, suggesting that
they might be candidates for less invasive monitoring [3]. This
finding led us to study the predictive value of the first biopsy,
obtained 7–12 days post-transplant. Thus, the aim of this study
was to determine whether very early data from a single biopsy are
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e36100sufficient to identify low-risk patients. Our analysis showed that
patients with absence of fibrin in the first biopsy rarely develop
CAV or graft failure during the next 10 years. Furthermore, the
high negative predictive value of the first-biopsy was comparable
to that of multiple biopsies obtained over three-months, implying
that patients with negative findings in the first biopsy potentially
could be monitored less invasively, thereby, avoiding the risk and
expense of multiple heart biopsy procedures.
Materials and Methods
Patients
Consecutive adult heart-transplant recipients transplanted from
August 1989 to August 2004 and followed prospectively until
September 2010, were candidates for study. Patients (n=172)
were included if they survived at least three months post-
transplantation, had serial endomyocardial biopsies performed in
the first three months, and had their coronary arteries examined
angiographically and/or histopathologically for CAV at annual
follow-ups. Of 241 candidates, 29 patients were excluded because
they had missing three-month biopsy data, either because they
died prior to three months (n=14) or because they were
transplanted at another institution (n=15); 38 survived three-
months but were excluded because they had incomplete biopsy
data; and two survived but were excluded because of missing
follow-up coronary evaluations. The study protocol was approved
by the Indiana University local Institutional Review Board and all
subjects signed a consent form.
Clinical management
All patients received triple-drug immunosuppression [4].
Rejection grades 2R-3R [5] were treated with steroids plus rabbit
antithymocyte globulin or OKT3 monoclonal antibody. Higher
dose immunosuppressants and clinical treatment strategies were
used at the physician’s discretion without knowledge of immuno-
histochemical data regarding markers of atherothrombosis and
endothelial activation.
Baseline (time-zero) endomyocardial biopsies were performed
on all of the 172 donor hearts at the time of transplantation but
before reperfusion. Additional biopsies were performed serially
during the first three months after transplantation, with the first
post-transplant biopsy obtained within a median 9 days of
transplantation.
Cytomegalovirus disease was defined during follow-up by
clinical symptoms and by cytopathologic-tissue culture evidence
of invasion. Cytomegalovirus prophylaxis with gancyclovir was
used in seronegative recipients of seropositive donors.
Outcome Criteria
CAV was evaluated in side-by-side comparisons of identical
projections of serial angiograms performed annually (Mean:
5.2561.0/patient) and diagnosed by evidence of coronary artery
narrowing or luminal irregularities either in left main or any
primary or branch vessels. CAV was considered severe if left main
stenosis was .70%, if two or more primary vessels had stenoses
.70%, or if branch stenoses were .70% in all three systems [6].
Presence and severity of CAV were determined by consensus of
two experienced angiographers unaware of immunohistochemical
biopsy results. In recipients who died before their first annual
angiogram, coronary arteries were examined histopathologically
and severe CAV was identified using similar criteria to those
described for angiographic evaluation. Graft failure due to CAV
was defined as: (a) death associated with CAV-related cardiac
allograft dysfunction, or (b) need for a second transplant due to
severe CAV.
Immunohistochemistry studies
Endomyocardial biopsies were tested immunohistochemically
for fibrin (NYBT2G1, Accurate, Westbury, NY; a-Fib Beta,
American Diagnostica, Stamford, CT); tissue plasminogen activa-
tor (tPA, ESP-1, American Diagnostica); antithrombin (A0296,
DAKO, Carpinteria, CA) and intercellular adhesion molecule-1
(ICAM-1, LB-2, Santa Cruz Biotechnology, Santa Cruz, CA).
Figure 1. Immunohistochemical characteristics of a thrombotic/activated microvasculature. Normal hearts (top row) have absence of
fibrin (Fib2), presence of microvascular antithrombin (AT+) and tissue plasminogen activator (tPA+) and absence of arterial endothelial ICAM-1
(ICAM-12). Abnormal thrombotic and activated hearts (bottom row) are characterized by presence of fibrin (Fib+), loss of microvascular antithrombin
(AT2) and tissue plasminogen activator (tPA2) and expression of arterial endothelial ICAM-1 (ICAM-1+). Original magnification 6640.
doi:10.1371/journal.pone.0036100.g001
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mer conjugated anti-mouse or fluorochrome-labeled anti-rabbit
F(ab’)2 fragments served as secondary antibodies (Molecular
Probes, Eugene, OR and Protos ImmunoResearch, Burlingame,
CA). Arteries were identified with fluorescein-labeled mouse
monoclonal antibody to human smooth muscle a-actin (1A4,
Sigma-Aldrich, St Louis, MO).
For immunofluorescence studies, tissue samples were embedded
in optimum cutting temperature compound (Miles, Elkhart, IN),
snap-frozen in liquid nitrogen and stored at 275uC. Cryostat
sections (4 mm) were air-dried overnight without fixation, and
immunostained. Rhodamine-conjugated anti-mouse and Alexa
Fluor 488 anti-rabbit or anti-mouse were used as secondary
antibodies.
For immunoperoxidase studies, slides from paraffin blocks were
antigen-retrieved using DAKO Target Retrieval solution (pH 6.0)
to expose antigens masked by formalin. Endogenous biotin was
blocked with avidin/biotin blocking system (DAKO) and endog-
enous peroxidase with 3% hydrogen peroxide. Fibrin antibody
was applied for 60 minutes at room temperature. Slides were
developed using DAKO’s EnVision+ Dual Link, HRP kit for
mouse primary antibodies in a DAKO Autostainer. Immunohis-
tochemical data were evaluated by two investigators unaware of
clinical outcome.
Coding of biopsy markers
Immunohistochemical data were scored as described by
Labarrere et al [3]. As illustrated in Figure 1 (top row), normal
hearts have absence of fibrin (Fib2), presence of microvascular
antithrombin (AT+) and tPA (tPA+) and absence of arterial
endothelial ICAM-1 (ICAM-1). Thrombotic and activated hearts,
shown in Figure 1 (bottom row), have myocardial fibrin deposits in
capillaries and cardiomyocytes (Fib+), loss of microvascular
antithrombin (AT2), loss of arteriolar tPA (tPA2) and expression
of arterial endothelial ICAM-1 (ICAM-1+). For predictive models
that used data from only the first biopsy, each of these signs was
scored either 0, if normal, or 1, if abnormal. For models that used
all biopsies obtained during the first three months, we calculated
the proportion of abnormal signs for each marker (e.g., if a patient
had four biopsies and three had fibrin deposits, the marker for
fibrin was scored: Fib+=3/4=.75 for that patient). Proportions
were re-scaled by a factor of 10 so that regression coefficients could
be interpreted as a 10% change in the proportion of abnormal
biopsies, a change in approximately one biopsy from normal to
abnormal for the typical patient. Four predictors were tested
representing the presence or absence of abnormality in the four
markers (Fib+,A T 2, tPA2, ICAM-1+).
Statistical model
Univariate logistic regression models were estimated using each
biomarker in turn as the sole predictor in the equation.
Multivariate stepwise models were then developed in two stages.
In stage-one, statistically significant biomarkers were identified by
stepwise backward elimination to establish base models. In stage-
two, clinical and laboratory covariates shown in Table 1, that were
found to be significantly associated with outcome in initial
bivariate analyses were forced into the base models. Because
time-zero biopsies revealed normal immunohistochemical markers
in all cases and exhibited no between-patient variation, they were
not considered as potential predictors in any of the regression
models.
Table 1. Summary of demographic and clinical variables
(Patients: n=172).
VARIABLE VALUE
Donor:
Age, mean years (6SD) 28.8 (611.2)
Sex (percent male) 78.5
Recipient:
Age, mean years (6SD) 48.7 (610.2)
Sex (percent male) 66.9
Race (percent white) 89.5
Body mass index (kg/m
2), mean (6SD) 26.5 (65.0)
Diabetics (%) 40.1
Insulin dependent diabetics (%) 31.4
Reason for transplantation:
Coronary artery disease (%) 45.9
Cardiomyopathy (%) 47.1
Other (%) 7.0
Ischemic time (minutes), mean
(±SD)
156.8 (656.6)
Smokers after transplantation (%) 7.6
Hypertensives (%) 89.0
Cholesterol (mmol/l):
Total cholesterol, mean (6SD) 5.4 (61.0)
LDL-C, mean (6SD) 2.6 (60.8)
HDL-C, mean (6SD) 1.2 (60.4)
Number of HLA mismatches: 01234
A/B (%) 0 5.8 16.3 47.1 30.8
DR (%) 7.00 39.0 54.0
Creatinine .123.8 mmol/l (%) 58.1
Ejection fraction, mean (%) (±SD) 54.3 (67.4)
2R-3R rejections (1
st 3-mos),
mean (±SD)
0.2 (60.4)
Biopsies (1
st 3-months),
mean (±SD)
5.2 (61.0)
CMV infections (% positive) 12.8
Cell Panel Reactive
Antibodies .0% (%)
8.1
Treatment:
Prednisone (%) 100.0
Cyclosporine (%) 94.2
Azathioprine (%) 68.0
Mycophenolate mofetil (%) 65.7
Tacrolimus (%) 11.0
Sirolimus (%) 7.0
Statins (%) 77.9
Calcium Channel Blockers (%) 77.9
ACE Inhibitors/ARBs (%) 43.0
All data based on entire sample of 172 patients. Abbreviations: SD: Standard
Deviation; LDL-C: low density lipoprotein cholesterol; HDL-C: high density
lipoprotein cholesterol; CMV: cytomegalovirus; ACE: Angiotensin-Converting
Enzyme; ARB: Angiotensin Receptor Blockers.
doi:10.1371/journal.pone.0036100.t001
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Using the method of Austin and Tu [7], regression models were
re-estimated for 200 bootstrap [8] samples drawn with replace-
ment from the original data. Bootstrap re-estimation of model
parameters is equivalent to performing multiple split-sample
validation estimates and provides assessments of model perfor-
mance without sacrificing sample size [9]. Statistically significant
biomarkers identified in stage one and covariates that were found
to be univariately associated with outcomes were included in final
multivariate models if those variables were retained in $60% of
the 200 bootstrapped models. A total of 36362=18 models were
derived to predict one-, five-, and 10-year odds of CAV, severe
CAV and graft failure due to CAV using markers from either the
first biopsy only, or from all biopsies available at three months.
The Youden Index calculated from receiver operating charac-
teristic (ROC) curves were used to identify optimum cut-off values
for the models [10]. Model performance was quantified by
evaluating sensitivity, specificity, and predictive accuracy. The C-
statistic (area under the ROC curve) was used to quantify
discriminative accuracy [11]. Models were further evaluated by
comparing the overall percentages of patients correctly classified.
Predicted values from ten-year models were stratified into three
groupings: (1) LOW RISK (lower 25% of risk distribution); (2)
MODERATE RISK (middle 50%) and (3) HIGH RISK (upper
25%) and separate Kaplan-Meier curves were constructed for
these risk groups.
Results
Demographic and clinical characteristics of the patient
population assessed at three months post-transplant are shown in
Table 1. Time-zero biopsies performed at the time of transplant
but before reperfusion all showed the characteristics of a
thromboresistant microvasculature (as illustrated in Figure 1, top
row). Because these baseline biopsies were all normal and
exhibited no variation they were not considered further in
regression models.
When evaluated in univariate regression models (Table 2),
individual markers from the first biopsy were statistically
significant and possessed good predictive value in most cases (C-
statistics: 0.50 to 0.77; odds ratios [ORs]: 0.95 to 13.04). The
presence of fibrin emerged as the most common univariate
predictor in first-biopsy models. This is in contrast with previous
analyses which showed that loss of tPA was the predominant
predictor in three-month models [3].
In final multivariate models (Tables 3, 4 and 5), presence of
fibrin with or without ICAM-1 expression was the most common
statistically significant predictor in first-biopsy models, and loss of
tPA was the dominant predictor in three-month models. Once the
odds associated with these markers were accounted for, none of
the other markers were able to explain additional odds.
The odds ratio (OR) in first-biopsy models represents the
multiplicative increase in risk associated with the presence of an
abnormal marker. In three-month models the OR is the
Table 2. Univariate logistic regression models using information from the first post-transplant biopsy (N=172 patients).
a
One-Year Risk Five-Year Risk Ten-Year Risk
(31 cases)
b (85 cases) (106 cases)
Model CAV: C OR CI C OR CI C OR CI
1 Fibrin 0.64 3.21 1.46–7.07 0.67 5.39 2.64–11.0 0.67 5.83 2.54–13.4
2 AT 0.64 3.30 1.45–7.50 0.67 4.36 2.29–8.29 0.70 5.68 2.77–11.7
3 tPA 0.63 2.89 0.98–4.79 0.67 4.77 2.44–9.34 0.68 5.60 2.58–12.1
4 ICAM-1 0.59 2.17 1.32–6.36 0.63 3.88 1.90–7.93 0.62 3.76 1.68–8.41
One-Year Risk Five-Year Risk Ten-Year Risk
(10 cases) (36 cases) (58 cases)
Severe CAV: C OR CI C OR CI C OR CI
5 Fibrin 0.75 8.96 1.84–43.7 0.67 4.05 1.87–8.79 0.67 4.38 2.22–8.66
6 AT 0.68 5.26 1.08–25.5 0.66 3.96 1.76–8.91 0.62 2.66 1.39–5.12
7 tPA 0.67 4.07 1.01–16.4 0.65 3.58 1.65–7.75 0.70 5.49 2.76–10.9
8 ICAM-1 0.50 1.02 0.25–4.10 0.62 2.86 1.33–6.17 0.61 2.67 1.35–5.29
One-Year Risk Five-Year Risk Ten-Year Risk
(7 cases) (18 cases) (31 cases)
Failure Due To CAV: C OR CI C OR CI C OR CI
9 Fibrin 0.77 13.04 1.53–111 0.75 8.75 2.73–28.0 0.67 4.14 1.84–9.32
10 AT 0.71 7.75 0.91–65.8 0.71 7.22 2.01–26.0 0.62 2.60 1.16–5.84
11 tPA 0.67 4.26 0.80–22.6 0.69 3.95 1.68–14.6 0.64 3.17 1.42–7.07
12 ICAM-1 0.51 0.95 0.18–5.05 0.64 3.45 1.27–9.33 0.61 2.73 1.23–6.08
Abbreviations: C: C-Statistic (Area under the ROC curve); OR: Odds Ratio; CI: Confidence Intervals; AT: Antithrombin; tPA: tissue Plasminogen Activator; ICAM-1:
Intercellular Adhesion Molecule-1.
aEach model uses one biomarker as the single predictor of CAV, severe CAV and failure due to CAV at one-, five-, and ten-years post-transplant.
bNumbers in parentheses (cases) represent the cumulative number of patients experiencing the indicated event at each follow-up interval.
doi:10.1371/journal.pone.0036100.t002
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proportion of abnormal biopsy results (equivalent to approximate-
ly one biopsy result over the first three months). As an example,
the three-month model predicting graft failure due to CAV at 10
years, which shows an OR for tPA of 1.31 (Table 5), indicates that
the 10-year odds of graft failure increases by a factor of 1.31 with
each 10% increase in the proportion of biopsies showing loss of
tPA in the first three months. A 20% increase in biopsies showing
loss of tPA (equivalent to approximately two biopsy results in the
first three months) increases the 10-year odds by
1.3161.31=1.7161.
Performance characteristics for all models are summarized in
Table 6. Considering positive and negative outcomes together,
first-biopsy and three-month models showed similar capacities to
classify patients correctly. The one exception was for 10-year
predictions of graft failure due to CAV where the three-month
model correctly classified a significantly higher percentage of
patients (87%) compared to the first-biopsy model (76%).
Positive predictive values for both first-biopsy and three-month
models tended to be low, with the lowest values associated with
one-year predictions. By contrast, negative predictive values were
high for both sets of models. For example, in first-biopsy models
patients with no evidence of fibrin deposition had a 99% chance of
avoiding graft failure due to CAV at one year, and continued to
have a 98% and 96% chance of being risk-free at five- and 10-
years (Table 6). Similarly, patients showing sustained levels of
microvascular tPA over the next three-months had a 100% chance
of avoiding graft failure due to CAV at one year, and continued to
have a 99% and 95% chance of being risk-free at five- and 10-
years, respectively. Thus, the earliest information available from a single
biopsy is sufficient to identify a subgroup of patients with very low odds of long-
term (10-year) graft failure due to CAV.
Kaplan-Meier curves using risk-stratified predictive values from
10-year regression models (Figure 2) showed significant time-to-
event differences by the log-rank test for CAV (p=.001), severe
CAV (p=.001), and failure due to CAV (p=.001) for both first-
biopsy and three-month models. Thus, first-biopsy models are
similar to three-month models not only in their predictions of
adverse event incidence, but also in their predictions of time to
event.
Discussion
Prediction models using information derived from a single
endomyocardial biopsy obtained within a median 9 days post-
transplant accurately identified heart transplant patients with
substantially reduced risk of developing long-term CAV and graft
failure.
The high negative predictive accuracies of our models have
important clinical implications. First, models that used only the
first biopsy had negative predictive values comparable to models
that used all biopsies available at three months, confirming our
hypothesis that a single early biopsy is sufficient to identify patients
with very low risk of long-term (10-year) graft failure due to CAV.
This finding implies that it may be possible to reduce the number
of follow-up biopsies and coronary angiographies for low-risk
patients, provided there is continued absence of symptoms or signs
of rejection. Moreover, multiple biopsies during the first three
months may be unnecessary in patients with no evidence of fibrin
deposits in the first biopsy. Of course, patients that are not
identified as low-risk would still need to be followed with definitive
monitoring. A potential strategy would be to follow low-risk
patients non-invasively with gene expression profiling, as has been
suggested for the monitoring of patients with low risk for rejection
Table 3. Final multivariate logistic regression models using first-biopsy-only or three-month biopsy data to predict CAV, severe
CAV, and graft failure due to CAV at one year post-transplant.
ONE-YEAR RISK of OUTCOME
CAV:
Using 1
st biopsy, only: Using all biopsies available at 3 months:
Predictor Variable OR CI Predictor Variable OR CI
Antithrombin 3.30 1.45–7.50 tPA 1.36 1.18–1.57
Ischemic time 0.99 0.99–1.00
SEVERE CAV:
Using 1
st biopsy, only: Using all biopsies available at 3 months:
Predictor Variable OR CI Predictor Variable OR CI
Fibrin 30.68 3.91–240.6 tPA 2.22 1.29–3.83
ICAM-1 0.08 0.01–0.60 Ischemic time 0.98 0.96–1.00
Statins 0.05 0.01–0.29 Statins 0.02 0.00–0.17
GRAFT FAILURE DUE TO CAV:
Using 1
st biopsy, only: Using all biopsies available at 3 months:
Predictor Variable OR CI Predictor Variable OR CI
Fibrin 38.70 4.00–374.8 tPA 1.81 1.08–3.03
ICAM-1 0.13 0.02–0.82
Abbreviations: OR: Odds Ratio; CI: 95% confidence interval for the OR; tPA: Tissue Plasminogen Activator; ICAM-1: Intercellular Adhesion Molecule-1.
Models on the left use information from the first biopsy only. Models on the right use information from all biopsies available in the first three months post-
transplantation.
doi:10.1371/journal.pone.0036100.t003
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monitoring protocols. In doing so, the complications and costs
associated with invasive heart biopsies would be reduced and
limited resources could be freed up for more intensive follow-up of
higher-risk patients.
The positive predictive accuracies of our models were not as strong as
the negative predictive accuracies, suggesting that it is harder to
identify high-risk than low-risk patients. A likely explanation is that
patients with evolving disease are eventually identified and treated
preventively during the 10-year follow-up interval, thereby
reducing the odds initially predicted based on prior three-month
data.
Absence of myocardial fibrin in the first biopsy and persistence
of microvascular tPA in all biopsies obtained during the first three
months emerged as the best independent predictors in most
multivariate models, suggesting that the underlying biological
process upon which statistical prediction is based evolves over time
during the first three months following transplantation. We
conclude that early absence of microthrombosis and continued
persistence of an intact fibrinolytic system are indicative of a
protective phenotype against long-term CAV and allograft failure.
Lack of antithrombin typifies a system that is failing to prevent
microvascular fibrin deposits. Thus, it is reasonable that loss of
antithrombin in the first-biopsy model would turn out to be the
best early predictor of CAV, and that the subsequent unchecked
accumulation of microvascular fibrin, secondary to the loss of
antithrombin, would be the best early predictor of severe CAV and
graft failure due to CAV. If microvascular fibrin continues to be
deposited due to the failure of antithrombin to prevent it, the
patient will still retain some capacity to remove it as long as there is
a sustained presence of tPA. However, if there is also loss of tPA,
fibrinolytic capacity will be diminished, fibrin deposition will
continue unabated, and the patient’s status will worsen. Thus, it is
reasonable that three-month models would pinpoint loss of tPA as
the single best independent predictor of long-term CAV and graft
failure.
In first-biopsy models it is noteworthy that ICAM-1 expression,
a marker of endothelial activation, appears with fibrin as a co-
predictor of severe CAV and graft failure at one year, indicating
that endothelial activation in the presence of microvascular fibrin
further heightens the odds of very early and very serious CAV.
This is consistent with observations from a transient cerebral
artery occlusion model showing that concomitant reduction of
both ICAM-1 expression and microvascular fibrin significantly
reduced brain injury and improved post-ischemic blood flow [12].
The importance of early microthrombosis, reduced fibrinolysis
and microvascular arterial endothelial activation for CAV and
graft failure has been previously demonstrated
[4,6,13,14,15,16,17,18]. Until now, however, the sequence in which
these markers emerge during the immediate post-transplant period
has not been well described and the prognostic significance of the
information contained in the first biopsy has been underappreci-
ated.
Table 4. Final multivariate logistic regression models using first-biopsy-only or three-month biopsy data to predict CAV, severe
CAV, and graft failure due to CAV at five years post-transplant.
FIVE-YEAR RISK of OUTCOME
CAV:
Using 1
st biopsy, only: Using all biopsies available at 3 months:
Predictor Variable OR CI Predictor Variable OR CI
Antithrombin 5.34 2.69–10.58 tPA 1.41 1.26–1.58
HLA-AB Mismatch 0.33 0.14–0.75 Recipient Sex (Male) 2.34 1.05–5.19
HLA-AB Mismatch 0.37 0.15–0.88
SEVERE CAV:
Using 1
st biopsy, only: Using all biopsies available at 3 months:
Predictor Variable OR CI Predictor Variable OR CI
Fibrin 4.13 1.77–9.68 tPA 1.45 1.23–1.71
MMF Regimen 0.36 0.15–0.84 MMF Regimen 0.45 0.18–1.11
Recipient Sex (Male) 2.22 0.84–5.90 Recipient Sex (Male) 4.17 1.41–12.31
HLA-AB Mismatch 0.41 0.16–1.06 HLA-AB Mismatch 0.33 0.11–0.95
Statins 0.36 0.15–5.90 Statins 0.27 0.10–0.73
GRAFT FAILURE DUE TO CAV:
Using 1
st biopsy, only: Using all biopsies available at 3 months:
Predictor Variable OR CI Predictor Variable OR CI
Fibrin 9.33 2.34–37.12 tPA 1.73 1.22–2.45
MMF Regimen 0.08 0.02–0.35 MMF Regimen 0.11 0.02–0.49
Statins 0.10 0.03–0.38 Statins 0.06 0.01–0.27
Abbreviations: OR: Odds Ratio; CI: 95% confidence interval for the OR; tPA: Tissue Plasminogen Activator; HLA: Human Leukocyte Antigen; MMF: Mycophenolate Mofetil.
Models on the left use information from the first biopsy only. Models on the right use information from all biopsies available in the first three months post-
transplantation.
doi:10.1371/journal.pone.0036100.t004
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ischemia-reperfusion (I/R) may be a trigger of coagulation
activation. The absence of a prothrombotic microvasculature in
all time-zero biopsies performed at the time of transplant and before
reperfusion further confirms that this phenotype developed after the
graft was placed into the recipient. These findings rule out the
possibility that our risk predictors are a consequence of brain
trauma to the donor or damage to the donor heart occurring
during the harvesting procedure. Likewise, they increase the
likelihood that abnormal markers detected in time-one biopsies are
related to I/R occurring immediately after transplantation. I/R
appear to damage endothelium by reducing anticoagulation,
increasing thrombogenicity and promoting vascular inflammation
and microthrombus formation leading to microinfarctions. Mass-
berg et al [19] observed massive ICAM-1-mediated microvascular
fibrinogen deposition and platelet adhesion as early as ten minutes
after reperfusion in an intestinal I/R model. Furthermore, I/R
induce production of reactive oxygen species, promoting endo-
thelial dysfunction and upregulation of ICAM-1 and P-selectin
[20]. Interestingly, the fibrin-derived peptide Bb15–42 (FX06) was
shown to significantly attenuate I/R injury in a heart transplant
model with extended cold ischemia by reducing infiltrating
leukocytes [21]. Pathophysiologically, I/R probably promotes
endothelial dysfunction and CAV by inducing platelet adhesion,
growth factor release, major histocompatibility class I and II
antigen upregulation, donor antigen release, and by promoting
adhesion molecule expression and smooth muscle cell proliferation
[22,23].
Considering the emergence of antibody-mediated rejection
(AMR) as a model of microcirculation injury and endothelial
activation [24,25] and its potential as a predictor of long-term
outcome [26,27], it is relevant to briefly discuss the relationship of
I/R with respect to AMR and our own findings [28]. Revelo et al
[29] recently showed that the combination of complement
components, HLA-DR and fibrin defines AMR in patients at risk
for allograft loss from cardiovascular causes and they recognized
fibrin as being particularly important for defining severe AMR
with a high likelihood of poor patient outcome. I/R may facilitate
endothelial susceptibility to a recipient’s antibody response leading
to further endothelial injury caused by AMR. Since complement
and antibody-mediated damage leads to vascular endothelial
injury with sometimes puzzling histologic consequences, the
additional evaluation of fibrin and HLA-DR over time could help
define persistent AMR in the presence of endothelial injury and
loss. A hypothesis worth testing is whether patients that develop a
prothrombotic microvasculature immediately following transplan-
Table 5. Final multivariate logistic regression models using first-biopsy-only or three-month biopsy data to predict CAV, severe
CAV, and graft failure due to CAV at ten years post-transplant.
TEN-YEAR RISK of OUTCOME
CAV:
Using 1
st biopsy, only: Using all biopsies available at 3 months:
Predictor Variable OR CI Predictor Variable OR CI
Antithrombin 8.73 3.81–20.04 Antithrombin 1.47 1.29–1.68
MMF Regimen 0.37 0.16–0.84 MMF Regimen 0.49 0.21–1.12
Recipient Sex (Male) 2.01 0.93–4.37 Recipient Sex (Male) 2.55 1.12–5.80
HLA-AB Mismatch 0.41 0.17–0.99 HLA-AB Mismatch 0.48 0.19–1.21
Statins 2.12 0.85–5.30 Rejections (1
st 3 mo) 0.40 0.13–1.21
SEVERE CAV:
Using 1
st biopsy, only: Using all biopsies available at 3 months:
Predictor Variable OR CI Predictor Variable OR CI
Fibrin 1.62 0.57–4.59 tPA 1.36 1.21–1.54
tPA 5.86 2.02–17.00 Recipient Sex (Male) 3.53 1.51–8.73
MMF Regimen 0.43 0.20–0.92 HLA-AB Mismatch 0.22 0.09–0.53
HLA-AB Mismatch 2.72 1.14–6.47 Ischemic time 0.99 0.99–1.00
Statins 0.22 0.09–0.54
GRAFT FAILURE DUE TO CAV:
Using 1
st biopsy, only: Using all biopsies available at 3 months:
Predictor Variable OR CI Predictor Variable OR CI
Fibrin 3.99 1.53–10.40 tPA 1.31 1.12–1.55
MMF Regimen 0.12 0.04–0.32 MMF Regimen 0.15 0.06–0.41
Statins 0.21 0.08–0.55 Recipient Sex (Male) 2.77 0.88–8.77
Statins 0.17 0.06–0.47
Abbreviations: OR: Odds Ratio; CI: 95% confidence interval for the OR; tPA: Tissue Plasminogen Activator; HLA: Human Leukocyte Antigen; MMF: Mycophenolate Mofetil.
Models on the left use information from the first biopsy only. Models on the right use information from all biopsies available in the first three months post-
transplantation.
doi:10.1371/journal.pone.0036100.t005
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evaluating C4d and CD68 within the grafts to establish the
relationship of those antibody reactivities to the pro- or anti-
coagulant status of the microvasculature.
From a prognostic perspective, it is important to ascertain how
much predictive information is actually added by incorporating a
new marker into the best current model, since new markers may
contain little or no additional information not already conveyed by
existing factors optimally combined [30]. For this reason, the
predictive accuracy of AMR-related factors should be judged by
comparing the best current model, with and without the AMR-
related factors included, using an overall indicator of model
discrimination such as the area under the ROC curve as the
criteria for judging the degree of improvement [31,32]. Since we
have shown here that our models have excellent negative predictive
accuracy, it would be especially important to know whether the
positive predictive accuracy of our models could be significantly
improved by adding AMR-related factors.
Our data suggest that graft failure may depend upon the extent
of very early post-transplant microvascular damage and the
capacity of the transplanted heart to remove microthrombi
through active fibrinolysis. Thus, therapies designed to de-escalate
hypercoagulability may be most effective if applied during the pre-
to peri- and early post-operative periods.
Our study has strengths and weaknesses. Weaknesses include
the utilization of angiography rather than intravascular ultrasound
[33] and the lack of baseline angiograms at the time of
transplantation. From a statistical point of view, our prediction
models ultimately need to be tested in other populations by other
investigators working in other settings in order to evaluate their
generalizability. However, our models did undergo cross-valida-
tion on repeated bootstrap samples. Cross-validation produces
estimates of a model’s likely performance on future data and
greatly reduces the likelihood of spurious variable selection that is
often the most important source of bias arising from stepwise
regression on a single sample [9]. Strengths include the relatively
large number of transplant patients, the long multi-year follow-up,
and the availability of a large immunohistochemical heart-biopsy
database.
The most important clinical message that emerges from our
data is that first-biopsy models are comparable to three-month
models as evidenced by their similar capacities to classify patients
correctly and to single out patients at low risk of CAV and graft
failure. The only exception was the superior performance of the
three-month model to correctly classify patients with respect to 10-
year graft failure due to CAV. The high negative predictive
accuracies associated with both, first-biopsy and three-month
models are especially noteworthy. Absence of a prothrombotic
microvasculature, even when observed as early as 9 days post-
transplant in a single biopsy, identifies patients that rarely develop
CAV and graft failure. These very low-risk patients are unlikely to
derive benefit from further invasive monitoring. Since repeated
heart biopsy procedures are both risky and expensive, our findings
have implications for both patients and payers. Of course, patients
that do not fall within this low-risk group should continue to be
followed under standard protocols using more definitive (invasive)
monitoring.
Although our findings show that it is possible, using markers
that are available within days of the transplant procedure, to
identify a subgroup of patients that almost never develops long-
term CAV or graft failure, they do not show what the impact on
patient outcomes would be if physicians used our prediction
models as a clinical tool to manage their transplant patients.
Clinical impact can only be demonstrated in a prospective
outcome trial in which some patients are randomly assigned to
receive usual care and others to a protocol that uses our models to
guide treatment decisions.
Table 6. Performance characteristics for first-biopsy (First) and three-month (All) biopsy models.
a
CAV SEVERE CAV GRAFT FAILURE DUE TO CAV
At 1 Year At 5 Years At 10 Years At 1 Year At 5 Years At 10 Years At 1 Year At 5 Years At 10 Years
Measure First All First All First All First All First All First All First All First All First All
C (ROC Area)
b 0.64 0.76 0.72 0.79 0.78 0.81 0.89 0.95 0.77 0.84 0.80 0.78 0.84 0.84 0.92 0.95 0.86 0.88
Sensitivity 0.69 0.81 0.79 0.78 0.62 0.76 0.90 1.00 0.74 0.83 0.74 0.82 0.86 1.00 0.83 0.94 0.87 0.77
Specificity 0.60 0.68 0.58 0.70 0.83 0.75 0.78 0.78 0.72 0.78 0.72 0.70 0.68 0.61 0.85 0.82 0.74 0.89
PPV 0.28 0.37 0.65 0.72 0.86 0.85 0.20 0.22 0.41 0.49 0.57 0.57 0.10 0.10 0.39 0.39 0.43 0.60
NPV 0.89 0.94 0.74 0.76 0.55 0.64 0.99 1.00 0.92 0.95 0.85 0.89 0.99 1.00 0.98 0.99 0.96 0.95
Cutoff Value
c 0.11 0.21 0.27 0.44 0.68 0.58 0.01 0.03 0.17 0.22 0.31 0.30 0.01 0.02 0.04 0.05 0.12 0.23
Pct Correct
d 0.62 0.70 0.69 0.74 0.70 0.75 0.79 0.79 0.72 0.79 0.73 0.74 0.69 0.63 0.85 0.83 0.76 0.87
e
Prevalence
f 0.19 0.50 0.63 0.06 0.20 0.33 0.04 0.10 0.18
Abbreviations: PPV: positive predictive value; NPV: negative predictive value.
aFirst-biopsy (First) and three-month (All) models show similar discriminative and predictive accuracy, particularly with respect to the prediction of severe CAV and graft
failure. Negative predictive values (NPV) are particularly high for both first-biopsy and three-month models, indicating that it is possible, using only information from the
first biopsy, to identify a patient subgroup at substantially reduced risk of developing long-term CAV or graft failure.
bC: C-statistics: A measure of the area under the receiver operating characteristic (ROC) curve. Equivalently, it is the proportion of all case versus non-case pairs that were
correctly classified by the model.
cCutoff value: The expected value from the logistic regression model that serves as the threshold for predicting the event in question. Patients with expected values that
exceed the cutoff are predicted to experience the event.
dPct Correct is the percent correctly classified by the model and includes both positive and negative classifications.
eThree-month model (All) is significantly better (p,.02) than the first-biopsy model (First) in classifying failure due to CAV at 10 years.
fPrevalence: the proportion of patients that experienced the indicated event by the indicated time point.
doi:10.1371/journal.pone.0036100.t006
First Post-Transplant Biopsy and CAV
PLoS ONE | www.plosone.org 8 April 2012 | Volume 7 | Issue 4 | e36100Figure 2. Kaplan-Meier curves using 10-year regression models. Kaplan-Meier curves of risk-stratified groupings derived from first-biopsy
versus three-month biopsy models showing time to (a) CAV, (b) severe CAV, and (c) failure due to CAV. Risk groupings were formed from the
distributions of the predictive probabilities from 10-year logistic regression models (low risk=lower 25%, moderate risk=middle 50%, and high
risk=upper 25%).
doi:10.1371/journal.pone.0036100.g002
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